Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast Cancer
Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.
Future Directions in the Management of HER2+ Breast Cancer
Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.
Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen
Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.
Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC
A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.
Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan
Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.
Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer
Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.
Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy
Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.
Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases
Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.
Dr. Modi on the Findings of DESTINY-Breast04 in HER2-Low Breast Cancer
Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.
Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC
Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.
Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?
Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.
Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer
Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.
Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer
Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.
Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC
Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.
Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer
Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512